戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 es the gastrointestinal safety advantages of etodolac.
2 t upper gastrointestinal (CSUGI) events with etodolac.
3 were inhibited by pre-surgical propranolol + etodolac.
4 creased event rates with naproxen 2-fold and etodolac 9-fold.
5  associated with a pretreatment regimen with etodolac, a nonsteroidal anti-inflammatory drug (NSAID),
6 cretion, whereas perioperative propranolol + etodolac administration blocked these effects.
7                                            R-etodolac also induces apoptosis against primary cells is
8                                            R-etodolac also inhibits viability of MM cells adherent to
9 mary outcome was the CSUGI event rate of the etodolac and naproxen groups without concomitant low-dos
10 ence in gastrointestinal event rates between etodolac and naproxen when low-dose aspirin was taken co
11 xed with four NSAIDs (ibuprofen, ketoprofen, etodolac, and nabumetone) and the active metabolite of n
12 g of a nonsteroidal antiinflammatory drug (R-etodolac), at concentrations that increased apoptosis of
13         Our data, therefore, indicate that R-etodolac circumvents drug resistance in MM cells at clin
14                    The apoptotic effect of R-etodolac could be controlled by manipulating cellular RX
15 rocedure (DEX group), or in combination with etodolac (DEX + ETO), ketorolac (DEX + KET), ibuprofen (
16 (NSAIDs) such as ibuprofen, naproxen sodium, etodolac, diclofenac, and ketorolac in this prototypic c
17                              Patients in the etodolac group received two 300 mg capsules 30 minutes p
18 y, neither IL-6 nor IGF-1 protects against R-etodolac-induced cytotoxicity in MM cells.
19      Immunoblot analysis demonstrates that R-etodolac induces apoptosis characterized by caspase-8, -
20 er of the nonsteroidal antiinflammatory drug etodolac inhibited tumor development and metastasis in t
21                                              Etodolac is a generic COX-2 selective inhibitor that red
22                                              Etodolac is a generic nonsteroidal anti-inflammatory dru
23    Previous in vitro studies have shown that etodolac is a selective inhibitor of cyclooxygenase (COX
24 g of the nonsteroidal anti-inflammatory drug etodolac, known as SDX-308, and its effects on osteoclas
25 ic and COX-2 inhibition, using propranolol + etodolac, maintained metastatic dormancy following lapar
26 teran patients (5596 patient-years) received etodolac or naproxen during a 3-year period without conc
27 GI events was .78% and .24% for naproxen and etodolac, respectively.
28 GI events was .99% and .24% for naproxen and etodolac, respectively.
29               In this study we report that R-etodolac (SDX-101), at clinically relevant concentration
30                                            R-etodolac specifically bound recombinant RXRalpha, inhibi
31  the first postsurgical dose was greater for etodolac than for the combination drug.
32      SDX-101 is another structural analog of etodolac that is already used in clinical trials for the
33                      Subcytotoxic doses of R-etodolac up-regulate myeloid cell leukemia-1 proapoptoti
34                      Compared with naproxen, etodolac was associated with a reduction in upper gastro
35 tends to evaluate the potential of combining etodolac with deformable-emulsomes, a flexible vesicular
36                         The combination of R-etodolac with Dex results in a highly synergistic cytoto